Texas researchers Maria Elena Bottazzi and Peter Hotez led development of the Corbevax patent-free Covid-19 vaccine. (Photo: Texas Medical Center)
Texas Team Applauded for Giving What Big Pharma Refuses: A Patent-Free Vaccine to the World
"We're not trying to make money. We just want to see people get vaccinated."
A small team of Texas researchers is being hailed for developing an unpatented Covid-19 vaccine to share with the world without personal profit, with some advocates asking, if they can do it, why can't Big Pharma?
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now."
Dubbed "the World's Covid vaccine," the inoculation--formally called Corbevax--is an open-source alternative to Big Pharma's patent-protected vaccines. Instead of being produced for profit, this shot could ultimately be manufactured around the world and made cheaply available to all without governmental or private legal retribution.
Common Dreams reported this week that Corbevax--developed jointly by Texas Children's Hospital, Houston's Baylor College, and the Indian pharmaceutical company Biological E. Limited--was authorized for emergency use in India amid a surge in infections driven by the highly contagious Omicron variant. Texas Children's Hospital says the new vaccine is at least 90% effective against the SARS-CoV-2 virus, and 80% or more effective against its Delta variant.
"We're not trying to make money," Peter Hotez, who led the Texas Children's Hospital team, told The Washington Post. "We just want to see people get vaccinated."
According to the Post, "Biological E. has ambitious plans to produce more than one billion doses of the vaccine in 2022." And while Hotez and Maria Elena Bottazzi at Baylor won't personally profit from vaccine they were instrumental in developing, the Post reports Baylor will take a fee.
Hotez said the Hyderabad-based pharma firm has about 150 million Corbevax doses ready to distribute, with 300 million more doses pre-ordered by the Indian government. The company hopes to ramp up production to 100 million monthly doses in order to better serve a nation in which only around 40% of the population are fully vaccinated.
Peter Maybarduk, director of the consumer advocacy group Public Citizen, said Thursday that "Texas Children's Hospital's commitment to sharing technology is a challenge to the pharma giants and the false narrative that vaccine production and medical innovation thrive through secrecy and exclusivity."
"If Texas Children's Hospital can do it," he asked, "why can't Pfizer and Moderna?"
The Post continued:
Unlike the vaccines of big-name manufacturers such as Pfizer-BioNTech and Moderna, the Texas Children's Hospital vaccine... is being shared patent-free... The ambition is to create a low-cost, open-source alternative to expensive and limited-supply mRNA vaccines for developing and under-vaccinated countries. And it won't stop at India: Hotez and Bottazzi are talking to other manufacturers around the world and have consulted with the World Health Organization to see how they can share the vaccine globally.
If everything goes to plan, manufacturers all around the world could produce their own versions of the Texas Children's Hospital vaccine, which uses older recombinant protein technology that many manufacturers already have experience with, rather than newer and potentially more complicated technology. Some advocates hope it could be a model for how vaccines should be developed and shared globally during a pandemic.
"This vaccine can be made locally all over the world, and we've now technology-transferred our Texas Children's vaccine to producers in India, Indonesia, Bangladesh, [and] Botswana," Hotez tweeted Tuesday. "Our Texas Children's Center does not plan to make money on this, it's a gift to the world."
While Big Pharma corporations took billions of dollars in public funding to help develop vaccines from which they then reaped enormous profits while often charging exorbitant prices, Hotez and Battazzi created Corbevax with $7 million, mostly from private investors. One of these, Austin vodka distiller Tito's, contributed $1 million to the effort.
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now," Hotez told the Post. "We wouldn't be having a discussion about Omicron."
Urgent. It's never been this bad.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just three days to go in our Spring Campaign, we're falling short of our make-or-break goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
A small team of Texas researchers is being hailed for developing an unpatented Covid-19 vaccine to share with the world without personal profit, with some advocates asking, if they can do it, why can't Big Pharma?
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now."
Dubbed "the World's Covid vaccine," the inoculation--formally called Corbevax--is an open-source alternative to Big Pharma's patent-protected vaccines. Instead of being produced for profit, this shot could ultimately be manufactured around the world and made cheaply available to all without governmental or private legal retribution.
Common Dreams reported this week that Corbevax--developed jointly by Texas Children's Hospital, Houston's Baylor College, and the Indian pharmaceutical company Biological E. Limited--was authorized for emergency use in India amid a surge in infections driven by the highly contagious Omicron variant. Texas Children's Hospital says the new vaccine is at least 90% effective against the SARS-CoV-2 virus, and 80% or more effective against its Delta variant.
"We're not trying to make money," Peter Hotez, who led the Texas Children's Hospital team, told The Washington Post. "We just want to see people get vaccinated."
According to the Post, "Biological E. has ambitious plans to produce more than one billion doses of the vaccine in 2022." And while Hotez and Maria Elena Bottazzi at Baylor won't personally profit from vaccine they were instrumental in developing, the Post reports Baylor will take a fee.
Hotez said the Hyderabad-based pharma firm has about 150 million Corbevax doses ready to distribute, with 300 million more doses pre-ordered by the Indian government. The company hopes to ramp up production to 100 million monthly doses in order to better serve a nation in which only around 40% of the population are fully vaccinated.
Peter Maybarduk, director of the consumer advocacy group Public Citizen, said Thursday that "Texas Children's Hospital's commitment to sharing technology is a challenge to the pharma giants and the false narrative that vaccine production and medical innovation thrive through secrecy and exclusivity."
"If Texas Children's Hospital can do it," he asked, "why can't Pfizer and Moderna?"
The Post continued:
Unlike the vaccines of big-name manufacturers such as Pfizer-BioNTech and Moderna, the Texas Children's Hospital vaccine... is being shared patent-free... The ambition is to create a low-cost, open-source alternative to expensive and limited-supply mRNA vaccines for developing and under-vaccinated countries. And it won't stop at India: Hotez and Bottazzi are talking to other manufacturers around the world and have consulted with the World Health Organization to see how they can share the vaccine globally.
If everything goes to plan, manufacturers all around the world could produce their own versions of the Texas Children's Hospital vaccine, which uses older recombinant protein technology that many manufacturers already have experience with, rather than newer and potentially more complicated technology. Some advocates hope it could be a model for how vaccines should be developed and shared globally during a pandemic.
"This vaccine can be made locally all over the world, and we've now technology-transferred our Texas Children's vaccine to producers in India, Indonesia, Bangladesh, [and] Botswana," Hotez tweeted Tuesday. "Our Texas Children's Center does not plan to make money on this, it's a gift to the world."
While Big Pharma corporations took billions of dollars in public funding to help develop vaccines from which they then reaped enormous profits while often charging exorbitant prices, Hotez and Battazzi created Corbevax with $7 million, mostly from private investors. One of these, Austin vodka distiller Tito's, contributed $1 million to the effort.
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now," Hotez told the Post. "We wouldn't be having a discussion about Omicron."
A small team of Texas researchers is being hailed for developing an unpatented Covid-19 vaccine to share with the world without personal profit, with some advocates asking, if they can do it, why can't Big Pharma?
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now."
Dubbed "the World's Covid vaccine," the inoculation--formally called Corbevax--is an open-source alternative to Big Pharma's patent-protected vaccines. Instead of being produced for profit, this shot could ultimately be manufactured around the world and made cheaply available to all without governmental or private legal retribution.
Common Dreams reported this week that Corbevax--developed jointly by Texas Children's Hospital, Houston's Baylor College, and the Indian pharmaceutical company Biological E. Limited--was authorized for emergency use in India amid a surge in infections driven by the highly contagious Omicron variant. Texas Children's Hospital says the new vaccine is at least 90% effective against the SARS-CoV-2 virus, and 80% or more effective against its Delta variant.
"We're not trying to make money," Peter Hotez, who led the Texas Children's Hospital team, told The Washington Post. "We just want to see people get vaccinated."
According to the Post, "Biological E. has ambitious plans to produce more than one billion doses of the vaccine in 2022." And while Hotez and Maria Elena Bottazzi at Baylor won't personally profit from vaccine they were instrumental in developing, the Post reports Baylor will take a fee.
Hotez said the Hyderabad-based pharma firm has about 150 million Corbevax doses ready to distribute, with 300 million more doses pre-ordered by the Indian government. The company hopes to ramp up production to 100 million monthly doses in order to better serve a nation in which only around 40% of the population are fully vaccinated.
Peter Maybarduk, director of the consumer advocacy group Public Citizen, said Thursday that "Texas Children's Hospital's commitment to sharing technology is a challenge to the pharma giants and the false narrative that vaccine production and medical innovation thrive through secrecy and exclusivity."
"If Texas Children's Hospital can do it," he asked, "why can't Pfizer and Moderna?"
The Post continued:
Unlike the vaccines of big-name manufacturers such as Pfizer-BioNTech and Moderna, the Texas Children's Hospital vaccine... is being shared patent-free... The ambition is to create a low-cost, open-source alternative to expensive and limited-supply mRNA vaccines for developing and under-vaccinated countries. And it won't stop at India: Hotez and Bottazzi are talking to other manufacturers around the world and have consulted with the World Health Organization to see how they can share the vaccine globally.
If everything goes to plan, manufacturers all around the world could produce their own versions of the Texas Children's Hospital vaccine, which uses older recombinant protein technology that many manufacturers already have experience with, rather than newer and potentially more complicated technology. Some advocates hope it could be a model for how vaccines should be developed and shared globally during a pandemic.
"This vaccine can be made locally all over the world, and we've now technology-transferred our Texas Children's vaccine to producers in India, Indonesia, Bangladesh, [and] Botswana," Hotez tweeted Tuesday. "Our Texas Children's Center does not plan to make money on this, it's a gift to the world."
While Big Pharma corporations took billions of dollars in public funding to help develop vaccines from which they then reaped enormous profits while often charging exorbitant prices, Hotez and Battazzi created Corbevax with $7 million, mostly from private investors. One of these, Austin vodka distiller Tito's, contributed $1 million to the effort.
"If we had even a fraction of the support that Moderna had, who knows, maybe the world would be vaccinated by now," Hotez told the Post. "We wouldn't be having a discussion about Omicron."